Atea Pharmaceuticals, Inc. Common Stock
AVIRAtea Pharmaceuticals, Inc. (AVIR) is a biotechnology company focused on developing innovative antiviral therapies for infectious diseases. The company leverages its proprietary research platform to discover and advance new treatments for viral illnesses, with an emphasis on respiratory viruses such as COVID-19. Atea collaborates with partners and clinical organizations to accelerate the development of its pipeline candidates.
Company News
Atea Pharmaceuticals presented modeling data showing their combination drug regimen of bemnifosbuvir and ruzasvir could potentially provide a short-duration, highly effective treatment for hepatitis C virus, with near-complete viral inhibition and a modeled cure time of 7-8 weeks.
Atea Pharmaceuticals will host a conference call on November 12, 2025, to discuss third quarter financial results and provide a business update, focusing on their antiviral drug development platform and HCV treatment research.
Atea Pharmaceuticals will host a conference call on August 7, 2025, to discuss second quarter 2025 financial results and provide a business update, focusing on their HCV treatment development program.
Atea Pharmaceuticals has dosed the first patient in its global Phase 3 C-FORWARD trial evaluating a combination regimen for the treatment of hepatitis C virus (HCV). The regimen has the potential to be a best-in-class option with a short treatment duration, low risk of drug-drug interactions, and convenience.
Atea Pharmaceuticals announced that it will present data from a Phase 2 clinical study of its regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) at the EASL Congress 2025. The regimen has the potential to be a best-in-class treatment option with a short duration, low risk of drug interactions, and convenience.
